Personalis Inc. (PSNL, Nasdaq)

[Illusive Man]

Natera and Personalis Partner for Personalized Monitoring in Oncology | Business Wire

 

[theantares]

Finita la favola? Cosa succede oggi?

 

[Belunat]

Ha rotto il supporto.
Che poi sia buona entro 12 mesi é un altro discorso

 

[ilovepablo]

Ha rotto il supporto.
Che poi sia buona entro 12 mesi é un altro discorso

Come mai secondo te è cambiato il sentiment?!

 

[Ligafree]

Personalis Inc expected to post a loss of 29 cents a share - Earnings Preview
24/02/2021 00:33 RSF
* Personalis Inc (PSNL.O) is expected to show a rise in quarterly revenue when it reports results on February 25.

* The Menlo Park, California-based company is expected to report ​a 10.6% increase in revenue to $20.073 million from $ 18.15 million a year ago​, according to the mean estimate of 7 analysts, based on Refinitiv data.

* Refinitiv's mean analyst estimate for Personalis Inc is for a loss of 29 cents per share. For the same quarter last year, the company reported a loss of 21 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." * The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Personalis Inc is $45​, about 24.6% above​ its last closing price of $33.94.​​​ * Previous quarterly performance (using preferred earnings measure). ​
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Sep. 30 2020 -0.26 -0.28 -0.27 Beat 2.6
Jun. 30 2020 -0.34 -0.34 -0.29 Beat 14.7
Mar. 31 2020 -0.27 -0.25 -0.29 Missed -13.7​
Dec. 31 2019 -0.24 -0.25 -0.21 Beat 16.8
Sep. -0.25​ -0.25 -0.22 Beat 11.1​
30​ 2019​
Jun. 30 2019 -0.30 -0.30 -0.89 Missed -199.2
​
This summary was machine generated February 23 at 23:33 GMT. All figures in US Dollars

 

[giammax88]

Mah...per adesso l'ho vista sempre rossa bel mio portafoglio ci vorrà un pochino per recuperare. Non mi è mai piaciuta fino in fondo...ma teniamo duro

 

[garen]

sarà scaramanzia .. ma rivoglio Umbi qui

 

[sibillo]

c'e' un calo molto forte di tute le societa' che trattano il genetico ,da crispr a invitae ....

 

[sibillo]

Vorrei fare la seguente domanda.
Ma quelli che entrano con molti soldi quando la societa' come personalis emette azioni e lo fanno a valori molto piu' alti degli attuali come si spiega?
Anche perche' la stessa cosa e' capitata con altri titoli del settore

 

[nellopennello]

Perché sono 'confident' che a lungo termine il prezzo sarà maggiore. Ma è pur vero che nessuno ha la palla di cristallo

 

[Gestivemto4321]

Vorrei fare la seguente domanda.
Ma quelli che entrano con molti soldi quando la societa' come personalis emette azioni e lo fanno a valori molto piu' alti degli attuali come si spiega?
Anche perche' la stessa cosa e' capitata con altri titoli del settore

È tutta una cricca,sono d’accordo l’uno con l’altro sottobanco e comunque si coprono sempre,in un senso e nell’altro.
Dove ci sono molti soldi,c’è sempre la manina fatata

 

[sibillo]

È tutta una cricca,sono d’accordo l’uno con l’altro sottobanco e comunque si coprono sempre,in un senso e nell’altro.
Dove ci sono molti soldi,c’è sempre la manina fatata

Preferisco pensare ad un calo che riguarda un settore, scendono tutti ma fino a dove?
Perché il settore è molto interessante, importante, prima o poi risalira', ma quando, a saperlo si potrebbe incrementare..

 

[Gestivemto4321]

Preferisco pensare ad un calo che riguarda un settore, scendono tutti ma fino a dove?
Perché il settore è molto interessante, importante, prima o poi risalira', ma quando, a saperlo si potrebbe incrementare..

Non so se scenderanno e fino dove. Rispondevo solo alla tua precedente questione.
È anche vero che come sulle ali dell’euforia i titoli hanno decuplicato,ed ancora sembravano a sconto,così se si girasse al ribasso avrebbero molta strada da fare.
A me le quotazioni sembrano fuori controllo. Capitalizzazioni di billions per fatturati di qualche centinaia di milioni,e non sto parlando di psnl. Ma il market ha sempre ragione. Io però sono totalmente liquido.
Ho perso anche dei gain in questo periodo,ma non mi sono fidato. Troppa vola,lascio il campo ai professional
Seguo e tornerò

 

[Ligafree]

February 25, 2021 - 4:01 pm
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2020.

Fourth Quarter Highlights

Record quarterly revenue of $20.2 million in the fourth quarter of 2020 compared with $18.2 million in the fourth quarter of 2019, an 11% increase
Record quarterly revenue of $7.6 million from biopharma and all other customers, excluding VA MVP, in the fourth quarter of 2020 compared with $4.4 million in the fourth quarter of 2019, a 73% increase
A total of 45 customers have placed orders for NeXT as of December 31, 2020, with 6 of those customers placing their first orders in the fourth quarter of 2020
Achieved milestone of completing more than 100,000 whole human genomes sequenced under the VA MVP contract
Launched new neoantigen prediction capabilities (called SHERPA(TM) and NEOPS(TM)) in the fourth quarter of 2020
"I'm proud to say that we were able to report record revenue once again this quarter and achieved our first $20 million revenue quarter, despite the impact from the COVID-19 pandemic. Biopharma revenue was strong and was a record high as some customers pushed to complete projects before the end of the year," said John West, Chief Executive Officer. "Recently, we announced a partnership with Natera that further validates our NeXT platform as a best-in-class tissue-sequencing front end, capable of detecting mutations in cancer that conventional exomes often miss. It also complements our whole exome liquid biopsy offering that we launched in August 2020 and NeXT Personal, our Minimal Residual Disease (MRD) offering that we expect to launch in 2021, providing Personalis with access to three distinct areas in the rapidly growing cancer monitoring market."

Fourth Quarter 2020 Financial Results

Revenues were $20.2 million in the three months ended December 31, 2020, up 11% from $18.2 million in the same period of the prior year.

Gross margin was 30.1% in the three months ended December 31, 2020, compared with 36.2% in the same period of the prior year.

Operating expenses were $19.4 million in the three months ended December 31, 2020, compared with $13.8 million in the same period of the prior year.

Net loss was $13.3 million in the three months ended December 31, 2020 and net loss per share was $0.34 based on a weighted-average basic and diluted share count of 39.0 million, compared with a net loss of $6.6 million and a net loss per share of $0.21 on a weighted-average basic and diluted share count of 31.2 million in the same period of the prior year.

Cash, cash equivalents, and short-term investments were $203.3 million as of December 31, 2020.

Full Year 2020 Financial Results

Revenues were $78.6 million for the year ended December 31, 2020, up 21% from $65.2 million in 2019.

Gross margin was 25.6% for the year ended December 31, 2020, compared with 33.9% in 2019.

Operating expenses were $62.3 million for the year ended December 31, 2020, compared with $44.5 million in 2019.

Net loss was $41.3 million for the year ended December 31, 2020 and net loss per share was $1.20 based on a weighted-average basic and diluted share count of 34.4 million, compared with a net loss of $25.1 million and a net loss per share of $1.39 on a weighted-average basic and diluted share count of 18.0 million in 2019.

First Quarter 2021 Outlook

Personalis expects the following for the first quarter of 2021:

Total Company revenues are expected to be approximately $20.3 million
Revenues from biopharma and all other customers, excluding VA MVP, are expected to be in the range of $5.6 million to $7.0 million
Net Loss is expected to be in the range of $14.0 million to $15.0 million

 

[agataflash]

Ma perché sto bagno di sangue?

 

[ilovepablo]

Ma perché sto bagno di sangue?

Veramente sono molto preoccupato su questo titolo. La mia peggior operazione degli ultimi mesi al momento visto il rosso pesante.

 

[Ligafree]

Morgan Stanley reports 97.41% increase in ownership of PSNL / Personalis, Inc. - 13F, 13D, 13G Filings - Fintel.io

Morgan Stanley reports 97.41% increase in ownership of PSNL / Personalis, Inc.
2021-02-16 - Morgan Stanley has filed a 13F-HR form disclosing ownership of 544,146 shares of Personalis, Inc. (USSNL) with total holdings valued at $19,920,000 USD as of 2020-12-31. Morgan Stanley had filed a previous 13F-HR on 2020-11-13 disclosing 275,646 shares of Personalis, Inc. at a value of $5,973,000 USD. This represents a change in shares of 97.41 percent and a change in value of 233.50 percent during the quarter.

 

[Ligafree]

Morgan Stanley Stick to Their Buy Rating for Personalis Inc By Investing.com

Morgan Stanley (NYSE:MS) analyst Tejas Savant maintained a Buy rating on Personalis (NASDAQSNL) Inc on Monday, setting a price target of $38, which is approximately 23.26% above the present share price of $30.83.

Savant expects Personalis Inc to post earnings per share (EPS) of -$0.27 for the first quarter of 2021.

The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Personalis, with an average price target of $41.86.
The analysts price targets range from a high of $50 to a low of $37.

In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $19.82 million and a net profit of -$9.65 million. The company's market cap is $1.2 billion.

According to TipRanks.com, Morgan Stanley analyst Tejas Savant is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 14.8% and a 72.73% success rate.

 

[Illusive Man]

SL @ 35, chiuso anche lo stoppino per vederlo nel portafoglio sui 31. Azioni genomics scaricate e con beta che mostrano troppo rischio atm. Resto in attesa.

 

[Asturias]

Tra non molto questa è qualche altra genomic stock la potremo acquistare a prezzi stracciati..